Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
3.150
+0.050 (1.61%)
Dec 5, 2025, 4:00 PM EST - Market closed
Lipocine Revenue
Lipocine had revenue of $114.57K in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $4.32M, down -45.44% year-over-year. In the year 2024, Lipocine had annual revenue of $11.20M, down -492.80%.
Revenue (ttm)
$4.32M
Revenue Growth
-45.44%
P/S Ratio
3.91
Revenue / Employee
$270,168
Employees
16
Market Cap
17.49M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
LPCN News
- 17 days ago - Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PRNewsWire
- 4 weeks ago - Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025 - PRNewsWire
- 4 weeks ago - Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek® - PRNewsWire
- 2 months ago - Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD) - PRNewsWire
- 3 months ago - Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference - PRNewsWire
- 3 months ago - Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025 - PRNewsWire
- 4 months ago - Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025 - PRNewsWire
- 5 months ago - Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression - PRNewsWire